Several other analysts have also recently weighed in on the company. HC Wainwright reissued a buy rating and set a $30.00 price objective on shares of Abeona Therapeutics in a report on Thursday, February 21st. ValuEngine cut Abeona Therapeutics from a hold rating to a sell rating in a report on Tuesday, February 5th. Maxim Group reissued a buy rating on shares of Abeona Therapeutics in a report on Wednesday, May 1st. Cantor Fitzgerald set a $29.00 price objective on Abeona Therapeutics and gave the stock a buy rating in a report on Tuesday, March 19th. Finally, Zacks Investment Research raised Abeona Therapeutics from a sell rating to a hold rating in a report on Wednesday, February 6th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus target price of $26.43.
Shares of NASDAQ:ABEO opened at $7.44 on Friday. The stock has a market cap of $365.77 million, a price-to-earnings ratio of -6.25 and a beta of 1.92. Abeona Therapeutics has a 1-year low of $6.26 and a 1-year high of $21.45. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.35 and a quick ratio of 4.37.
Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Monday, March 18th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.42) by $0.06. The firm had revenue of $0.50 million during the quarter, compared to analysts’ expectations of $1.66 million. Abeona Therapeutics had a negative return on equity of 45.58% and a negative net margin of 960.91%. As a group, sell-side analysts expect that Abeona Therapeutics will post -1.5 EPS for the current year.
In related news, Director Stefano Buono bought 70,000 shares of the firm’s stock in a transaction dated Thursday, April 11th. The stock was bought at an average cost of $7.80 per share, for a total transaction of $546,000.00. Following the transaction, the director now owns 20,980 shares of the company’s stock, valued at $163,644. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Stephen B. Howell bought 4,000 shares of the firm’s stock in a transaction dated Monday, April 8th. The shares were bought at an average price of $7.77 per share, with a total value of $31,080.00. Following the completion of the transaction, the director now directly owns 6,000 shares in the company, valued at approximately $46,620. The disclosure for this purchase can be found here. 33.60% of the stock is currently owned by insiders.
Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. increased its stake in Abeona Therapeutics by 1.6% in the third quarter. BlackRock Inc. now owns 2,220,116 shares of the biopharmaceutical company’s stock valued at $28,418,000 after purchasing an additional 35,610 shares during the period. Dimensional Fund Advisors LP acquired a new position in Abeona Therapeutics in the third quarter valued at $933,000. Man Group plc acquired a new position in Abeona Therapeutics in the third quarter valued at $267,000. Teachers Advisors LLC increased its stake in Abeona Therapeutics by 75.6% in the third quarter. Teachers Advisors LLC now owns 98,192 shares of the biopharmaceutical company’s stock valued at $1,257,000 after purchasing an additional 42,261 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in shares of Abeona Therapeutics by 7.6% in the third quarter. Vanguard Group Inc. now owns 1,539,008 shares of the biopharmaceutical company’s stock valued at $19,699,000 after acquiring an additional 108,333 shares in the last quarter. Institutional investors own 67.53% of the company’s stock.
About Abeona Therapeutics
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Featured Story: What are the qualifications of a portfolio manager?
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.